Jade Biosciences (JBIO) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.42

Estimate

-$0.79

Surprise

+46.6%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Jade Biosciences (JBIO) reported a narrower loss than forecast — adjusted EPS of -$0.42 against the -$0.79 estimate (a 46.6% beat on a still-unprofitable quarter).

• Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update — fiscal.ai, 2026-11-13
• Jade Biosciences Q3 EPS $(0.42) Beats $(0.71) Estimate — benzinga, 2026-11-13

TrendMatrix currently rates JBIO Sell at 5.2/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +46.6% surprise compares with a +3.8% four-quarter average. Next scheduled report: 2027-03-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$16.14

Price target

$16.82

Stop

$15.01

Upside to target

+4.2%

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.03B

P/E (fwd)

-7.1

52-week range

$10.97–$28.00

Off 52-week high

42.4%

RSI (14)

63

Volume vs avg

0.73×

Score today

5.2/10